drugset / Trial / NCT01423526

A Single Dose Study of DWP10292 in Healthy Male Subjects

NCT01423526

Phase 1 Completed 52 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedSingle-groupTriple-blindBasic science

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of orally administrated DWP10292 in healthy male volunteers.

Timeline

Start
2011-08
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject DWP10292 Unknown Oral

Indications

No indication recorded.